Scott Chan moved from China to the U.S. with family at the age of ten. He passed the rigorous entrance exam and attended the merit-based Stuyvesant High School, widely held to be best public school in New York City. He earned undergraduate degrees from New York University followed by an MBA degree from the Zicklin School of Business at Baruch College.
Shortly thereafter Scott partnered with Dr. Stephen Leeb on numerous financial publications. Today, he serves as the lead analyst for Real World Investing and The Complete Investor.
Mr. Chan is an avid baseball fan and enjoys outdoor activities in his spare time. A multicultural person, he reads Chinese and speaks fluent Mandarin and Cantonese Chinese.
Core Growth Portfolio biotech holding Biogen Idec (Nasdaq: BIIB) has gained about 35 percent since the end of May as fears of a generic threat and revenue slowdown subsided. It set a new 52-week high last Friday after weekly sales of Tecfidera (the face of Biogen’s MS franchise) grew 3.1… Read More
Merger talk between T-Mobile (Nasdaq: TMUS) and Sprint (NYSE: S) is again heating up. While a marriage between the third and fourth largest U.S. national mobile carriers may not be a great thing for consumers, from an investment perspective it looks like it could be a "win-win" situation for both companies. Read More
Parents in China are spending an increasing amount of money on tutoring to try to give their kids an edge in the highly competitive race to enter the best universities. Many students begin to prepare for the college entrance exam in elementary school. The explosive demand has created tremendous opportunity for tutoring operators. Read More
A Chinese online gaming stock has fallen sharply since reporting quarterly results that did not match the previous quarter's blowout numbers. We think the slowdown in mobile-game growth is temporary and the acceleration of growth in its ecommerce business bodes well for a rebound. Read More
Although Apple (Nasdaq: AAPL) is already, by far, the world's largest company by market cap, it has consistently proven that with one great product, it can still grow. A company trading at a very reasonable valuation, AAPL offers a high floor and we think it is a must-own for investors. Read More
After a heated run beyond the $40 mark, this biotech stock has taken a hard fall over the past 7 weeks. Yet nothing significant has happened to its intriguing pipeline. The share price and expectation have reset and it's time to consider buying some shares. Read More
The emergence of social media has changed the world, and it has opened up some tantalizing new investment opportunities for investors. However, before buying into the hype, it's important to keep in mind that ultimately Wall Street will demand to see growth and profits. Read More